CBA Pharma, Inc. has filed the New Drug Application (NDA) for the use of CBT-1® as an adjunct to chemotherapy in all cancer types with MDR. As a lead up to filing the NDA.

CBA Pharma, Inc. conducted eight clinical trials to evaluate CBT-1® as a MDR modulator. Thirty-eight medical centers or cancer treatment centers participated in clinical trials. Patients were registered with the cancer types of Acute Myelogenous Leukemia, Breast, Non-Hodgkin’s Lymphoma, Hodgkin’s disease, Non-Small Cell Lung Cancer, Multiple Myeloma, Gallbladder, Pancreatic, Gastrointestinal Tract, Neuroendocrine, Mesothelioma, Small Cell Lung Cancer, Bladder, Head & Neck, Ovarian, Prostate, and Sarcoma.